Nasal Glucagon · Baqsimi

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Severe Hypoglycemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
EU
  • Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Product first approved 2019EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Severe Hypoglycemia
NCT02402933 · Eli Lilly and Company
2015-03 – 2015-08 · Hypoglycemia, Diabetes Mellitus
What this study did
NCT02171130 · Eli Lilly and Company
2014-05 – 2015-08 · Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
What this study did
Other / comorbidity
NCT03421379 · Eli Lilly and Company
2018-02-21 – 2018-08-20 · Diabetes Mellitus
What this study did
NCT01959334 · Eli Lilly and Company
2013-09 – 2013-12 · Drug-specific Antibodies, Diabetes Mellitus
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT01997411 · Eli Lilly and Company
2013-11 – 2015-01 · Diabetes Mellitus, Type 1
What this study did
Phase 2 (1)
Severe Hypoglycemia
NCT01556594 · Eli Lilly and Company
2012-03 – 2012-07 · Hypoglycemia
What this study did
Phase 1 (7)
Severe Hypoglycemia
Other / comorbidity
NCT04992312 · Eli Lilly and Company
2022-03-24 – 2023-11-05 · Type 1 Diabetes
What this study did
NCT03765502 · Eli Lilly and Company
2018-11-19 – 2019-01-03 · Healthy
What this study did
NCT02806973 · Eli Lilly and Company
2015-01 – 2015-04 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT02806960 · Eli Lilly and Company
2014-06 – 2014-08 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT02778100 · Eli Lilly and Company
2013-03 – 2013-04 · Common Cold
What this study did
NCT02778113 · Eli Lilly and Company
2011-10 – 2011-11 · Healthy
What this study did

Competitive landscape

Other Glucagon receptor (agonist) drugs

dasiglucagon. Compare all 2 Glucagon receptor (agonist) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Severe Hypoglycemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nasal Glucagon (Baqsimi): this drugApprovedPeptideGlucagon receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Dasiglucagon (Zegalogue)
ApprovedUS marketing discontinued
PeptideGlucagon receptor (agonist)Partial signal
NCT03378635: Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 10 to 10) | Placebo 40 minutes (95% CI 30 to 40) | GlucaGen® 1.0 mg 12 minutes (95% CI 10 to 12)
NCT03667053: Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 8 to 12) | Placebo 30 minutes (95% CI 20 to 45) | GlucaGen® 1.0 mg 10 minutes (95% CI 8 to 12)

Upcoming events

No upcoming readouts on record for this asset.